Amgen Inc. (AMGN) Collaborates on Ending Anti-OX40 Clinical Studies

Group 1: Clinical Trials and Safety Concerns - Kyowa Kirin Co., Ltd. is discontinuing all ongoing clinical trials involving rocatinlimab due to newly emerging safety issues, including additional malignancy cases [2] - The total number of malignancy events across studies remained below expected background levels, but the pattern raised scientific concerns linked to OX40 pathway activity [3] - Amgen and Kyowa Kirin determined that possible risks could exceed anticipated therapeutic benefits for patients, leading to the formal end of the clinical studies [3] Group 2: Financial Announcements - Amgen's Board approved a cash dividend of $2.52 per share for the second quarter of 2026, with payouts scheduled for June 5, 2026 [4] - Stockholders listed at the end of trade on May 15, 2026, will receive the dividend [4] Group 3: Investment Perspective - Amgen is recognized as one of the best kid-friendly stocks to invest in [1] - While Amgen has potential as an investment, certain AI stocks are considered to offer greater upside potential and less downside risk [5]